Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics ...
Pursuant to the transaction with Telix, ImaginAb has retained its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed by numerous pharmaceutical ...
Team uses AI and quantum computing to target 'undruggable' cancer protein
Research co-led by University of Toronto researchers and Insilico Medicine has demonstrated the potential of quantum ...